MedPath

LymeX Diagnostics Prize Announces Phase 3 Winners, Paving the Way for Advanced Lyme Disease Diagnostics

The LymeX Diagnostics Prize has revealed its Phase 3 winners, each awarded $420,000, in a competition aimed at accelerating the development of innovative diagnostics for Lyme disease. These teams, including BlueArc Biosciences Inc. and Drexel University College of Medicine, have developed promising tests for early detection and treatment tracking of Lyme disease. The competition, supported by a $10 million pledge, now moves into Phase 4, focusing on clinical validation studies and FDA submissions.

LymeX Diagnostics Prize Announces Phase 3 Winners

The LymeX Diagnostics Prize, a significant initiative aimed at accelerating the development of Lyme disease diagnostics, has announced its Phase 3 winners. This phase of the competition, supported by a more than $10 million pledge from the Steven & Alexandra Cohen Foundation, focuses on nurturing diagnostics towards FDA review and clearance. The winners, each awarded $420,000, have developed innovative solutions for the early detection and treatment tracking of Lyme disease.

The Winning Teams and Their Innovations

  • BlueArc Biosciences Inc. (La Jolla, California): Developed an ultrasensitive and specific blood test for the direct detection of B. burgdorferi infection from the first symptoms of Lyme disease using standard laboratory equipment.
  • Drexel University College of Medicine (Philadelphia): Created a small-volume serum test using glycan biomarkers to detect active Lyme disease infection and track treatment response.
  • HelixBind Inc. (Marlborough, Massachusetts): Designed a direct-from-blood molecular assay that can detect DNA from intact Borrelia spirochetes utilizing a proprietary, readily automated sample-to-answer process.
  • Massachusetts General Hospital (Boston): Developed a plasma and extracellular fluid test depleting human background material from samples and detecting low-abundance nucleic acid from tick-borne pathogens.
  • Northwestern University Feinberg School of Medicine (Chicago): Created a test using monoclonal antibodies in conjunction with both immuno-PCR and lateral flow to rapidly detect a unique B. burgdorferi biomarker in blood and urine.

Phase 3 Overview and Support

From May to October 2024, the teams benefited from webinar modules, mentorship, and networking opportunities. They also received non-financial in-kind support from industry leaders Labcorp and Quest Diagnostics, enhancing their understanding of the diagnostics industry and clinical laboratory operations. The competition's judging panel, composed of experts in various relevant fields, evaluated submissions based on official Phase 3 evaluation criteria, including engagement with the FDA, analytical performance data, and clinical performance study protocols.

Looking Ahead: Phase 4

Phase 4 of the LymeX Diagnostics Prize will focus on supporting clinical validation studies and completing regulatory submissions to the FDA, with up to $3 million in prizes awarded. The competition anticipates additional prizes for FDA clearance, marking a significant step forward in the fight against Lyme disease.
This initiative represents a critical advancement in the development of effective diagnostics for Lyme disease, offering hope for improved detection and treatment outcomes for patients worldwide.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Essex Bio-Technology Completes Phase 3 Study for Wet-AMD Treatment

Essex Bio-Technology Limited has successfully completed the final patient visit in an international multi-centre phase 3 clinical study for HLX04-O, a bio-pharmaceutical aimed at treating wet-AMD. This study compares HLX04-O's efficacy and safety with ranibizumab, addressing a significant gap in the Chinese market.

Pharming's Leniolisib Shows Positive Phase 3 Data in Young Children with APDS

Pharming's leniolisib demonstrated positive topline results in a Phase 3 trial for children aged 4-11 with Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS).
The study showed improvements in lymphoproliferation and immunophenotype correction, consistent with results from trials in older patients.

FDA Accepts sBLA for Glofitamab Plus Chemotherapy in Relapsed/Refractory DLBCL

The FDA has accepted Roche's sBLA for glofitamab combined with gemcitabine and oxaliplatin (GemOx) for relapsed/refractory DLBCL patients ineligible for autologous stem cell transplant.
The sBLA is based on the phase 3 STARGLO trial, which demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to rituximab plus GemOx.

Lundbeck Launches Phase III Trial for Rare Neurological Disorder Treatment

Lundbeck has initiated a Phase III clinical trial for a novel drug aimed at treating a rare neurological disorder, marking a significant step in its development program.
The late-stage study will evaluate the efficacy and safety of the investigational drug in patients affected by this debilitating condition.

Diamyd Medical's DIAGNODE-3 Trial Reaches Recruitment Milestone, Eyes Accelerated Approval

Diamyd Medical's DIAGNODE-3 trial, a Phase 3 study for Type 1 Diabetes, has recruited 180 patients, surpassing the target for its early readout planned in March 2026.
The early readout is designed to support a potential accelerated Biologics License Application (BLA) submission to the FDA, leveraging the Fast Track designation.

Biogen and UCB's Dapirolizumab Pegol Shows Promise in Phase III Lupus Trial

Dapirolizumab pegol (DZP) plus standard of care demonstrated a statistically significant 49.5% response rate in SLE patients, compared to 34.6% with standard care alone.
The Phase III PHOENYCS GO trial met its primary endpoint, with a treatment difference of 14.6% and a p-value of 0.0110, indicating clinical benefit.

Recent Approvals and Phase III Readouts Highlight Pharmaceutical R&D Advances

Several pharmaceutical and biotech companies have recently announced significant progress in their R&D pipelines, including multiple drug approvals across various therapeutic areas.
Phase III clinical trials have yielded important readouts, providing insights into the efficacy and safety of novel treatments for diverse diseases.

Allyx Therapeutics Receives $3.3 Million NIH Grant for ALX-001 Clinical Studies in Alzheimer's and Parkinson's

Allyx Therapeutics has been awarded a $3.3 million NIH grant to support clinical studies of ALX-001, a novel oral therapy for Alzheimer's and Parkinson's disease.
The funding will facilitate a Phase I pharmacokinetic drug-drug interaction study to assess ALX-001's impact on cytochrome P450 enzymes.

LAG-3 Inhibitors Show Promise in Cancer Immunotherapy, Market Expected to Surge

The LAG-3 inhibitors market is poised for substantial growth, projected to exceed USD 3 billion by 2029, driven by increasing adoption in cancer therapy.
Opdualag, the first approved LAG-3 therapy, has demonstrated significant commercial success, generating substantial revenue and paving the way for further drug development.

Spectral Medical Expands Tigris Trial for PMX Hemoperfusion Device in Septic Shock

Spectral Medical has added three new clinical trial sites for its Phase III Tigris trial, evaluating the PMX hemoperfusion device for septic shock and endotoxemia.
The Tigris trial, guided by the Endotoxin Activity Assay, aims to enroll 150 patients to assess the effectiveness of PMX in removing sepsis-causing endotoxins.

Reference News

[1]
LymeX Diagnostics Prize announces Phase 3 winners - LymeDisease.org
lymedisease.org · Jan 16, 2025

The LymeX Diagnostics Prize announced Phase 3 winners in a $10+ million competition to advance Lyme disease diagnostics....

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy